Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice

Abstract

Breast cancer is a prevalent malignancy in the present day, particularly affecting women as one of the most common forms of cancer. A significant portion of patients initially present with localized disease, for which curative treatments are pursued. Conversely, another substantial segment is diagnosed with metastatic disease, which has a worse prognosis. Recent years have witnessed a profound transformation in the prognosis for this latter group, primarily due to the discovery of various biomarkers and the emergence of targeted therapies. These biomarkers, encompassing serological, histological, and genetic indicators, have demonstrated their value across multiple aspects of breast cancer management. They play crucial roles in initial diagnosis, aiding in the detection of relapses during follow-up, guiding the application of targeted treatments, and offering valuable insights for prognostic stratification, especially for highly aggressive tumor types. Molecular markers have now become the keystone of metastatic breast cancer diagnosis, given the diverse array of chemotherapy options and treatment modalities available. These markers signify a transformative shift in the arsenal of therapeutic options against breast cancer. Their diagnostic precision enables the categorization of tumors with elevated risks of recurrence, increased aggressiveness, and heightened mortality. Furthermore, the existence of therapies tailored to target specific molecular anomalies triggers a cascade of changes in tumor behavior. Therefore, the primary objective of this article is to offer a comprehensive review of the clinical, diagnostic, prognostic, and therapeutic utility of the principal biomarkers currently in use, as well as of their clinical impact on metastatic breast cancer. In doing so, our goal is to contribute to a more profound comprehension of this complex disease and, ultimately, to enhance patient outcomes through more precise and effective treatment strategies.

Exploring the Immunological Profile in Breast Cancer: Recent Advances in Diagnosis and Prognosis through Circulating Tumor Cells

“…The success of immunotherapy against CTCs hinges on factors, such as CTC immunogenicity, antigen expression, and the immune system's capacity to recognize and eliminate these cells [146]. The TME, replete with immune-suppressive elements, further modulates the efficacy of immunotherapies against CTCs [147]. In the oncology landscape, immunotherapy's transformative impact is evident through ICIs, such as ipilimumab, nivolumab, and pembrolizumab [145].…”

Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition

“…Biomarker-based breast cancer classification has led to significant advancement in the treatment of breast cancer patients [ 1 , 2 ]. Target-specific therapeutic agents such as human epidermal growth factor receptor 2 (HER2)-targeting trastuzumab or lapatinib and estrogen receptor (ER)-targeting tamoxifen have been successfully used in the clinic [ 3 , 4 , 5 ]. Among the breast cancer subtypes, triple-negative breast cancer (TNBC), which accounts for 20% of all breast cancer cases, is the most aggressive subtype with high metastasis and mortality rates [ 6 ].…”